This is a Phase 3, randomised, active controlled, multicentre extension study to investigate
the long-term safety and efficacy of PA21, a phosphate binder, for control of
hyperphosphataemia in dialysis patients. This is an extension study to PA-CL-05A
(NCT01324128), subjects have already been enrolled and have been treated with study
medication for at least 24 weeks.